The Rome III classifi cation system treats functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C) as distinct disorders, but this distinction appears artifi cial, and the same drugs are used to treat both. This study ' s hypothesis is that FC and IBS-C defi ned by Rome III are not distinct entities.
INTRODUCTION
Th e Rome III classifi cation system for functional gastrointestinal disorders treats functional constipation (FC) and constipation predominant irritable bowel syndrome as distinct disorders, and implies that they have diff erent pathophysiological mechanisms and therefore would require diff erent treatment approaches ( 1 ) . Th e basis of FC is thought to involve delayed transit through the colon and / or failure to relax the pelvic fl oor muscles during attempted defecation whereas the pathophysiology of irritable bowel syndrome with constipation (IBS-C) is believed to involve a disorder of brain -gut interaction with a predominant symptom of pain or discomfort ( 2 ) .
When diagnoses of IBS-C or FC are made using the Rome III criteria there is no overlap because the Rome III criteria specifically exclude assigning a diagnosis of FC to a patient who fulfi lls the criteria for IBS-C (see Table 1 ) ( 1 ). However, no rationale for this exclusion was provided by the authors of the Rome I ( 3 ) or subsequent versions of the Rome criteria, and some clinicians regard this requirement as artifi cial. Moreover, it is noteworthy that both pro-kinetics such as Tegaserod ( 4 ), Prucalopride ( 5 ) and chloride channel agonists such as Lubiprostone ( 6 ) have been found in clinical trials to be eff ective for the treatment of both IBS-C and FC ( 7 ) .
Th e purpose of this study was to test the hypothesis that FC and IBS-C as defi ned by the Rome III criteria are not distinct Inability of the Rome III Criteria to Distinguish Functional Constipation From Constipation-Subtype Irritable Bowel Syndrome entities. To test this, we fi rst examined the overlap between FC and IBS-C that would result if the requirement that no patient meeting criteria for IBS-C could also be diagnosed with FC were removed. Second, using the published Rome III criteria, which exclude overlap, we classifi ed patients into mutually exclusive categories and compared the symptom characteristics of FC and IBS-C. Th ird, we assessed the degree of switching between these diagnoses that occurs over time; if the disorders are distinct subjects should either recover or retain their original diagnosis, whereas if they have substantially similar etiologies, one might expect subjects to alternate between these diagnoses. We also investigated patient characteristics that predict switching diagnoses over a 12-month period.
METHODS
Th is is a secondary analysis of a larger prospective study on risk factors for chronic constipation and the impact of chronic constipation on quality of life and health care costs. Th e study was carried out at Group Health Cooperative (GHC), which is a health management organization. Group Health members aged 18 years or older who made at least one clinic visit to a primary care provider between 1 September 2005 and 31 December 2005, and were enrolled at the GHC for all of the previous 5 years, were screened for inclusion in the study. Subjects with a history of gastrointestinal resection except appendectomy or cholecystectomy, and subjects with any ICD-9CM codes for gastrointestinal cancer were excluded.
Th e screening and recruitment algorithm is shown in Figure 1 . We fi rst identifi ed 1,100 subjects for screening who had received a clinical diagnosis of constipation (ICD9CM code 569.0X) at a clinical visit between 1 September 2005 and 31 December 2005, and 1,700 age-and sex-matched subjects who had not received a clinical diagnosis of constipation at GHC for at least the last 5 years. Matching was accomplished by stratifi ed sampling: Based on a previous study of the membership of Group Health Cooperative, ( 8 ) we were aware (a) that approximately 2 / 3 of patients with a clinical diagnosis of constipation would meet Rome III criteria for FC, (b) that a substantial number of people who had not consulted physicians for constipation would nevertheless meet symptom criteria for FC, and (c) that constipation is more prevalent in women than men and in older versus younger people. We therefore designed a quota sampling scheme in which we sampled approximately twice as many controls as we anticipated obtaining for constipated patients in each age stratum within each sex. Th ere were 1,707 who completed the enrollment questionnaires (66.2 % response rate) of whom 432 met the Rome III criteria for FC or IBS-C, and 336 (77.8 % ) of these completed the 12-month survey.
Ethics approval
Th e study was approved by the Institutional Review Boards for the Protection of Human Subjects at both the University of North Carolina at Chapel Hill and the GHC. As granted by both review boards, informed consent was inferred from completion and return of questionnaires, and subjects were not required to return a signed consent document. Th e cover letter sent with the survey contained all elements of informed consent. 
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Survey questionnaires
Th e questionnaires completed by study subjects included the Rome III Diagnostic Questionnaire modules for functional constipation, IBS and bloating. Th e development and validation of this questionnaire has been previously described ( 9, 10 ) . In addition to a Rome III diagnosis, these questionnaires were scored for two indices of symptom severity: (i) the number of constipation symptoms experienced, based on the 6 Rome III FC symptoms (see Table 1 ); and (ii) the Constipation Severity Scale (CSS), a score calculated as the sum of the 5-point ordinal ratings (0 = never, 1 = sometimes, 2 = oft en, 3 = most of the time, 4 = always) for the six Rome III functional constipation questions. Th e CSS was previously validated ( 11 ) . Th e frequency of abdominal pain or discomfort was assessed by the Rome III question, " In the last 3 months, how oft en did you have discomfort or pain anywhere in your abdomen for any reason? " Response choices were " never, " " less than one day a month, " " one day a month, " " 2 -3 days a month, " " one day a week, " " more than one day a week, " and " every day. " Demographic information such as age, gender, race, ethnicity, marital status, personal education as well as personal annual income were ascertained at the enrollment survey. Th e baseline and follow-up surveys incorporated the ShortForm Health Survey (SF-12), and the Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire (which measures the degree of impairment in quality of life due to constipation). Th e SF-12 is scored for mental and physical component summary scores ( 12 ) . Th e PAC-QOL covers 4 dimensions pertaining to constipation (physical discomfort, worries and concerns, psychosocial discomfort, and satisfaction), and the results are presented as a total QOL impact score ( 13 ) . Th e survey also included the Brief Symptom Inventory (BSI), which provides an overall measure of psychological distress inferred from symptoms of anxiety, depression, and somatization ( 14 ) . BSI scale scores were adjusted for sex diff erences by converting them to T-scores before statistical analysis.
Data analysis
Statistical analyses utilized SPSS soft ware (version 15.0 for Windows, SPSS Inc., Chicago, IL). Th e χ 2 -test was used for dichotomous variables, Student ' s t -test was used for continuous variables, and the Mann -Whitney U -test was used for ordinal scaled data. A two-tailed P value of P < 0.05 was considered signifi cant. Demographic factors that were signifi cantly diff erent between the groups at baseline were treated as potential confounders, and were controlled for using an analysis of covariance.
RESULTS

Overlap between IBS-C and FC at baseline
Two hundred and one patients met the Rome III criteria for IBS-C and 231 met criteria for FC at baseline. Th e Rome III diagnostic criteria for FC include the condition that if a subject fulfi lls criteria for IBS, they cannot be diagnosed as FC ( 1 ), yet 180 of the 201 IBS-C patients would have met criteria for FC if this restriction were not present ( Figure 2 ). Th us, without this restriction a total of 411 cases would fulfi ll criteria for FC of whom 43.8 % would also fulfi ll criteria for IBS-C, and 89.5 % of the 201 IBS-C cases would also fulfi ll the criteria for FC. Th e Venn diagram in Figure 2 illustrates this overlap at baseline. Table 2 compares the demographic characteristics of the 231 subjects who fulfi lled the published Rome III criteria for FC (no overlap with IBS-C permitted) and the 201 who fulfi lled the criteria for IBS-C at baseline. FC patients were older and had a higher educational level; therefore in the subsequent analyses, we adjusted for both of these factors as potential confounders (except for non-parametric tests of signifi cance). Table 3 describes the baseline bowel symptoms and psychosocial indices of these two groups. Th ere was a greater frequency of abdominal discomfort or pain among the IBS-C patients, and this was expected because the diagnostic criteria for IBS require pain and / or discomfort. However, 44.8 % of FC patients also reported experiencing some abdominal pain or discomfort within the past 3 months (although they did not meet other symptom criteria for a diagnosis of IBS). Paradoxically, the IBS-C patients had signifi cantly more constipation symptoms than their FC counterparts and a signifi cantly worse CSS score, indicating a more severe degree of constipation at baseline. IBS-C subjects also had a greater impairment on the PAC-QOL, signifi cantly worse psychological distress on the BSI, and greater impairment in the SF-12 Mental Composite Score.
Demographic differences between FC and IBS-C
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Inability of Rome Criteria to Distinguish FC From IBS-C
Symptom and psychosocial differences between FC and IBS-C patients
Switching of diagnoses
Twelve months aft er they enrolled in the study, 79 / 195 (40.5 % ) of those with FC had recovered and were no longer constipated (that is, no longer met the FC or IBS-C criteria), and 30 / 141 (25.5 % ) of those who had IBS-C at enrollment were no longer constipated (that is, no longer met criteria for IBS-C or FC). Th e proportion who recovered was nearly twice as great for FC compared with IBS-C ( Table 4 ) . To investigate the tendency to switch diagnoses over time, we excluded patients who recovered and examined the diagnoses of those who retained symptoms of constipation at 12 months: Approximately one third (36 / 111) of FC patients switched and met criteria for IBS-C or IBS with mixture of constipation and diarrhea (IBS-M) at 12 months, which was matched by a third (36 / 109) of IBS-C patients who switched and met criteria for FC at 12 months follow-up.
Differences in baseline characteristics of patients who switched diagnoses
To explore the possible reasons why IBS-C and FC patients switch diagnoses, we compared the constipation and pain characteristics at baseline of subjects who switched vs. those who retained their original diagnostic labels. Among patients with FC at baseline, those who switched to IBS-C at 12 months reported more frequent abdominal pain or discomfort at baseline (median of less than 1 day / month vs. never, P = 0.001 by Mann -Whitney U -test) as well as at 12 months (median of 2 -3 days / mo vs. never, P < 0.001) compared with those who remained FC patients. Conversely, IBS-C patients who switched to FC had less frequent abdominal pain or discomfort at baseline (median of 2 -3 days / month vs. 1 day / week, P < 0.001), and at 12 months (median of less than 1 day / month vs. 1 day / week, P < 0.001) as compared with those who remained IBS-C.
When those who retained their diagnoses for 12 months were compared with those who switched ( Table 5 ) , there was no difference in the number of constipation symptoms at baseline or in their baseline CSS scores. Th is was true for both the group who had FC at baseline and the group with IBS-C at baseline. Th e PAC-QOL, SF-12, and BSI scores also failed to predict whether subjects would switch or remain in the same diagnostic category. Age and education were treated as covariates in these analyses.
DISCUSSION
Th e Rome criteria were designed as a tool to categorize patients with functional gastrointestinal diseases into distinct diagnoses based on their presenting symptoms ( 1 ). Our study is the fi rst to 
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functional constipation and IBS-C. In our study, we showed that at baseline there was a large overlap between the diagnostic labels of IBS-C and FC, with approximately 90 % of the IBS-C patients fulfi lling the diagnostic criteria for FC, and nearly half of the FC patients meeting the criteria for IBS-C. Th is speaks of the fact that while the Rome III criteria for these two conditions require them to be mutually exclusive, in reality these criteria are unable to clearly separate IBS-C from FC patients based on presenting symptoms. One of the few longitudinal studies that attempted to determine the stability of FGID symptoms was a natural history population survey by Halder et al. , which describes a high rate of turnover in the symptom status of patients ( 17 ) . Th eir data showed that nearly equal proportions of IBS-C subjects became FC and vice-versa over follow-up. As compared with Halder ' s study, we focused on patients with a clinical diagnosis of constipation, with the exclusion of any concurrent gastrointestinal organic pathology, rather than relying on a population incidence. As such, we had much larger subject numbers and data that we believe can be extrapolated to patients in the clinical setting.
What is also unique about our study is that we investigated patients who had symptoms of constipation that were severe enough to result in a medical clinic visit, and who received a clinical diagnosis of constipation from their physician. Th is contrasts with the studies of largely healthy subjects in previous publications. We focused on the constipation characteristics of these patients, and so had detailed data relating to symptom characteristics, quality of life and other measures, which allowed us to test for diff erences between the FC and IBS-C patients and the factors that predicted the stability of their diagnoses.
Abdominal pain or discomfort is the hallmark symptom of IBS ( 18 ) , raising the question of whether this symptom uniquely distinguishes IBS-C from FC. Our data confi rm that IBS-C patients have more frequent pain or discomfort than FC patients and that FC patients who had more pain at baseline or who developed more abdominal pain or discomfort during the 12-month followup period were more likely to switch from a diagnosis of FC to a evaluate in a large population of subjects with constipation, the ability of the Rome III criteria to achieve this distinction. Th e data show that the Rome III criteria for FC and IBS-C does not separate patients into distinct groups. Th is is shown by the following observations:
(1) Diagnostic overlap -If the artifi cial requirement that FC and IBS-C cannot be diagnosed in the same person is suspended, 89.5 % of those with IBS-C also meet criteria for FC, and conversely 43.8 % of patients fulfi lling criteria for FC also meet criteria for IBS-C ( Figure 2 ). Th is implies that IBS-C is a subset of FC. (2) Lack of specifi city in symptom profi les -While IBS-C patients report more frequent pain or discomfort than FC, 44 % of patients meeting only FC criteria also report some pain or discomfort. Moreover, IBS-C patients paradoxically report more severe constipation than FC patients. (3) Switching diagnostic labels -When patients who recover from constipation are excluded, approximately 1 / 3 of patients with each diagnostic label at study enrollment switch to the other diagnostic label by 12 months follow-up.
Previous investigators have reported a similar overlap in symptoms in population-based samples and have recognized that the " splitting " of functional gastrointestinal disorders into discrete diagnoses may not be practical. Locke et al. ( 15 ) showed in a population survey that there is a signifi cant overlap between functional GI symptoms that have been used to defi ne symptom complexes. Of relevance, they suggested that up to 6.5 % of the population surveyed had an IBS / constipation overlap. In an early study that alluded to the ambiguity in the defi nition of constipation, Probert et al. ( 16 ) showed that the likelihood of having IBS was signifi cantly increased in those who met the Rome defi nition of constipation. However, none have directly addressed the issue of the precision of the Rome criteria for distinguishing between the diff erent diagnostic labels assigned to constipated patients, namely between Frequency of abdominal discomfort was described using an ordinal scale : 0 = never; 1 = < 1 day a month, 2 = 1 day a month, 3 = 2 -3 days a month, 4 = 1 day a week, 5 = > 1 day a week, 6 = every day.
Inability of Rome Criteria to Distinguish FC From IBS-C diagnosis of IBS-C. However, the symptom of abdominal pain or discomfort lacked specifi city for IBS-C diagnosis: 44 % of patients meeting only criteria for FC at baseline had some abdominal pain or discomfort, and a reduction in the level of abdominal pain or discomfort was about as likely to occur and to result in a change of diagnosis as compared with an increase in abdominal pain or discomfort. Th ese observations are consistent with the hypothesis that the diff erences between IBS-C and FC in abdominal pain are quantitative but not qualitative diff erences, that is, they only refl ect diff erences in the frequency of pain or discomfort. Further studies investigating the pathophysiological mechanisms for pain and discomfort in these two groups are needed. Psychological distress is another symptom that has been thought to be more closely linked to IBS than to FC. Our data confi rm greater psychological distress in IBS-C compared with FC, but neither baseline levels of psychological distress nor changes in psychological distress from baseline to the end of follow-up were signifi cant predictors of changes in diagnosis from baseline to 12 months follow-up.
A limitation of this study is that we did not measure relevant physiological parameters such as whole gut transit time, pelvic fl oor function during defecation, or pain thresholds. It is possible that these physiological variables could identify pathophysiologically distinct groups of patients with constipation. Th e patients in this study were also older than average for IBS patients in other series although ages were typical for functional constipation. It is diffi cult to see how these limitations could aff ect our conclusion that the Rome III criteria in their current form do not identify distinct groups of patients with FC and IBS-C.
Th ere are implications on a number of fronts -First, the Rome symptom-based diagnoses are based on the premise that they " breed true " across clinical and population groups and provide a framework for identifying patients for research and in collecting accurate epidemiological data ( 1 ). Our fi ndings suggest that a redefi nition of the Rome criteria, as they pertain to patients with constipation, may be needed to avoid confusion in treatment trials and disease prevalence reporting. Second, there are clinical ramifi cations. Physicians seeking to assign a concrete disease label to their patients or base their treatment algorithms upon making a defi nitive diagnosis will likely be frustrated as they fi nd their patients switching between disorders, and will wonder if their diagnosis was accurate in the fi rst place.
Conclusions
In summary, the overlap in symptoms between IBS-C and FC and the tendency to alternate between diagnoses suggest that the Rome III criteria for IBS-C and FC may not identify etiologically distinct groups of patients. FC and IBS-C appear to be conditions that are quantitatively diff erent, with IBS-C being more severe than FC, but they appear to be qualitatively similar. Th erefore, rather than being separate diagnoses, we proposed that they are actually part of the same condition, anchored on diff erent ends of the spectrum of severity.
In trying to defi ne the true diff erences between FC and IBS-C, we propose that the current Rome criteria based on symptom definition are inadequate, but we acknowledge that physiological tests of motility or transit might identify qualitative diff erences between FC and IBS-C.
